S4. E11. 百靈佳殷格翰的人類處方用藥研發歷程​ Our Human Pharma Research and Development Pipeline 

 

百靈佳殷格翰明確的知道自己的目標:提供系列具有突破性的藥物,以改善世界各地病患的生活。創新,就是我們的出發點。我們有約100個臨床和臨床前試驗,有極大機率能在2025年前產出15種新藥;我們長期扮演造浪者的角色,率領眾人穩定前行。

 

Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the world. This starts with innovation. With a pipeline of around 100 clinical and pre-clinical projects, with the potential to deliver up to 15 new medicines by 2025, we continue our track record of long-term innovation-led performance.

 

 

(S4. E11)s4.e11_1

 

 

(S4. E11)s4.e11_2

 

 

(S4. E11)s4.e11_3

 

 

(S4. E11)s4.e11_4

友善服務

列印內容